{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:17:05Z","timestamp":1792318625814,"version":"4.4.0"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11010-023-04825-w","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T09:02:22Z","timestamp":1694163742000},"page":"1937-1955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A review of immune modulators and immunotherapy in infectious diseases"],"prefix":"10.1007","volume":"479","author":[{"given":"P.","family":"Sangeetha Vijayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanan Parayanthala","family":"Valappil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"8","key":"4825_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/occmed\/kqm110","volume":"57","author":"D Baxter","year":"2007","unstructured":"Baxter D (2007) Active and passive immunity, vaccine types, excipients and licensing. Occup Med 57(8):552\u2013556","journal-title":"Occup Med"},{"key":"4825_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD et al (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235\u2013271","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"4825_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/reg2.97","volume":"5","author":"L Florez-Sampedro","year":"2018","unstructured":"Florez-Sampedro L, Song S, Melgert BN (2018) The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung. Regeneration 5(1):3\u201325","journal-title":"Regeneration"},{"issue":"1","key":"4825_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0378-8741(94)90020-5","volume":"42","author":"A Puri","year":"1994","unstructured":"Puri A, Saxena R, Saxena RP et al (1994) Immunostimulant activity of Nyctanthes arbor-tristis L. J Ethnopharmacol 42(1):31\u201337","journal-title":"J Ethnopharmacol"},{"issue":"6","key":"4825_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3389\/fpls.2015.00655","volume":"25","author":"I Jantan","year":"2015","unstructured":"Jantan I, Ahmad W, Bukhari SN (2015) Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials. Front Plant Sci 25(6):655","journal-title":"Front Plant Sci"},{"key":"4825_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/B978-0-12-394591-4.00004-0","volume":"62","author":"CC Wen","year":"2012","unstructured":"Wen CC, Chen HM, Yang NS (2012) Developing phytocompounds from medicinal plants as immunomodulators. Adv Bot Res 62:197\u2013272. https:\/\/doi.org\/10.1016\/B978-0-12-394591-4.00004-0","journal-title":"Adv Bot Res"},{"key":"4825_CR7","first-page":"1","volume":"2013","author":"K Shashank","year":"2013","unstructured":"Shashank K, Abhay KP (2013) Chemistry and biological activities of flavonoids: an overview. Sci World J 2013:1\u20136","journal-title":"Sci World J"},{"issue":"2","key":"4825_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3736\/jcim20110201","volume":"9","author":"S Kumar","year":"2011","unstructured":"Kumar S, Gupta P, Sharma S et al (2011) A review on immunostimulatory plants. Chin J Integr Med 9(2):117\u2013128","journal-title":"Chin J Integr Med"},{"issue":"4","key":"4825_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.immuni.2010.09.014","volume":"33","author":"RN Germain","year":"2010","unstructured":"Germain RN (2010) Vaccines and the future of human immunology. Immunity 33(4):441\u2013450","journal-title":"Immunity"},{"issue":"8","key":"4825_CR10","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2217\/fvl.15.60","volume":"10","author":"JM Brotherton","year":"2015","unstructured":"Brotherton JM (2015) HPV prophylactic vaccines: lessons learned from 10 years experience. Future Virol 10(8):999\u20131009","journal-title":"Future Virol"},{"issue":"9","key":"4825_CR11","first-page":"4007","volume":"192","author":"IH Frazer","year":"2014","unstructured":"Frazer IH (2014) Development and implementation of papillomavirus prophylactic vaccines. J Immunol Res 192(9):4007\u20134011","journal-title":"J Immunol Res"},{"issue":"9","key":"4825_CR12","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1086\/374419","volume":"187","author":"SA Plotkin","year":"2003","unstructured":"Plotkin SA (2003) Vaccines, vaccination, and vaccinology. JInfect Dis 187(9):1349\u20131359","journal-title":"JInfect Dis"},{"key":"4825_CR13","doi-asserted-by":"crossref","unstructured":"James E.\u00a0CroweJr. Prevention of fetal and early life infections through maternal\u2013neonatal immunization. In: Remington, Klien, Wilson, Nizet, Maldonado Eds.\u00a07th ed. Philadelphia, PA: Saunders\/Elsevier; 2011.pp.1212\u20131230","DOI":"10.1016\/B978-1-4160-6400-8.00038-9"},{"issue":"4","key":"4825_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33(4):492\u2013503","journal-title":"Immunity"},{"issue":"2","key":"4825_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/vaccines3020320","volume":"3","author":"AD Pasquale","year":"2015","unstructured":"Pasquale AD, Preiss S, Silva FT et al (2015) Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines 3(2):320\u2013343","journal-title":"Vaccines"},{"issue":"1","key":"4825_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1749-6632.2010.05787.x","volume":"1213","author":"EF Nicholls","year":"2010","unstructured":"Nicholls EF, Madera L, Hancock RE (2010) Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann N Y Acad Sci 1213(1):46\u201361","journal-title":"Ann N Y Acad Sci"},{"issue":"1-2","key":"4825_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.imlet.2012.06.002","volume":"147","author":"TR Ghimire","year":"2012","unstructured":"Ghimire TR, Benson RA, Garside P et al (2012) Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett 147(1\u20132):55\u201362","journal-title":"Immunol Lett"},{"key":"4825_CR18","doi-asserted-by":"crossref","unstructured":"Vogel F. Immunologic adiuvants. Vaccines: Expert Consult. 2008:59\u201371.","DOI":"10.1016\/B978-1-4160-3611-1.50009-X"},{"issue":"4","key":"4825_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9(4):287\u2013293","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4825_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0008-8749(89)90011-7","volume":"121","author":"JL Grun","year":"1989","unstructured":"Grun JL, Maurer PH (1989) Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 121(1):134\u2013145","journal-title":"Cell Immunol"},{"issue":"6","key":"4825_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0151","volume":"1","author":"D Metcalf","year":"2013","unstructured":"Metcalf D (2013) The colony-stimulating factors and cancer. Cancer Immunol Res 1(6):351\u2013356","journal-title":"Cancer Immunol Res"},{"key":"4825_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/CBO9780511663376","volume-title":"The hematopoietic colony-stimulating factors: From Biology to Clinical Applications","author":"D Metcalf","year":"1995","unstructured":"Metcalf D, Nicola NA (1995) The hematopoietic colony-stimulating factors: From Biology to Clinical Applications. Cambridge University Press, Cambridge, UK, pp 1\u2013327"},{"issue":"10","key":"4825_CR23","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/s41423-020-0439-2","volume":"18","author":"YM Chuang","year":"2021","unstructured":"Chuang YM, He L, Pinn ML et al (2021) Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis. Cell Mol Immunol 18(10):2393\u20132401","journal-title":"Cell Mol Immunol"},{"key":"4825_CR24","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","volume":"30","author":"DT O\u2019Hagan","year":"2012","unstructured":"O\u2019Hagan DT, Ott GS, De Gregorio E, Seubert A (2012) The mechanism of action of MF59\u2014an innately attractive adjuvant formulation. Vaccine 30:4341\u20134348. https:\/\/doi.org\/10.1016\/j.vaccine.2011.09.061","journal-title":"Vaccine"},{"key":"4825_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coi.2017.07.010","volume":"47","author":"DT O\u2019Hagan","year":"2017","unstructured":"O\u2019Hagan DT, Friedland LR, Hanon E, Didierlaurent AM (2017) Towards an evidence based approach for the development of adjuvanted vaccines. Curr Opin Immunol 47:93\u2013102. https:\/\/doi.org\/10.1016\/j.coi.2017.07.010","journal-title":"Curr Opin Immunol"},{"key":"4825_CR26","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1073\/pnas.0903181106","volume":"106","author":"G Galli","year":"2009","unstructured":"Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T et al (2009) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 106:7962\u20137967. https:\/\/doi.org\/10.1073\/pnas.0903181106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4825_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/erv.11.23","volume":"10","author":"DT O\u2019Hagan","year":"2011","unstructured":"O\u2019Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G (2011) MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 10:447\u2013462. https:\/\/doi.org\/10.1586\/erv.11.23","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"4825_CR28","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","volume":"14","author":"EJ Ko","year":"2018","unstructured":"Ko EJ, Kang SM (2018) Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother 14(12):3041\u20133045","journal-title":"Hum Vaccin Immunother"},{"key":"4825_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","volume":"2197","author":"N Kayraklioglu","year":"2021","unstructured":"Kayraklioglu N, Horuluoglu B, Klinman DM (2021) CpG oligonucleotides as vaccine adjuvants. Methods Mol Biol 2197:51\u201385","journal-title":"Methods Mol Biol"},{"key":"4825_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/14760584.2014.863715","volume":"13","author":"H Shirota","year":"2014","unstructured":"Shirota H, Klinman DM (2014) Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines 13:299\u2013312. https:\/\/doi.org\/10.1586\/14760584.2014.863715","journal-title":"Expert Rev Vaccines"},{"key":"4825_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.intimp.2010.12.005","volume":"11","author":"S Wang","year":"2011","unstructured":"Wang S, Han Q, Zhang G et al (2011) CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase. Int Immunopharmacol 11:406\u2013411","journal-title":"Int Immunopharmacol"},{"key":"4825_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/784740","author":"S Duggal","year":"2012","unstructured":"Duggal S, Chugh TD, Duggal AK (2012) HIV and malnutrition: effects on immune system. ClinDev Immunol. https:\/\/doi.org\/10.1155\/2012\/784740","journal-title":"ClinDev Immunol"},{"key":"4825_CR33","doi-asserted-by":"crossref","unstructured":"Sachan S, Dhama K, Latheef SK, et al. Immunomodulatory Potential of Tinospora cordifolia and CpG ODN [TLR21 Agonist] against the very virulent, infectious Bursal disease virus in SPF Chicks. Vaccines. 2019;7[3]:106.","DOI":"10.3390\/vaccines7030106"},{"key":"4825_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13733","author":"F Seirafianpour","year":"2020","unstructured":"Seirafianpour F, Mozafarpoor S, Fattahi N et al (2020) Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.13733","journal-title":"Dermatol Ther"},{"issue":"2","key":"4825_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1941874412458678","volume":"3","author":"LS Gensler","year":"2013","unstructured":"Gensler LS (2013) Glucocorticoids: complications to anticipate and prevent. The Neurohospitalist 3(2):92\u201397","journal-title":"The Neurohospitalist"},{"issue":"1","key":"4825_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335(1):2\u201313","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"4825_CR37","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1371\/journal.pmed.0030343","volume":"3","author":"LJ Stockman","year":"2006","unstructured":"Stockman LJ, Bellamy R, Garner P (2006) SARS: systematic review of treatment effects. PLoS Med 3(9):1525\u20131531","journal-title":"PLoS Med"},{"key":"4825_CR38","doi-asserted-by":"crossref","unstructured":"Arabi Y.M., Mandourah Y., Al-Hameed F., Sindi A.A., Almekhlafi G.A., Hussein M.A., Jose J., Pinto R., Al-Omari A., Kharaba A., Almotairi A., Al Khatib K., Alraddadi B., Shalhoub S., Abdulmomen A., Qushmaq I., Mady A., Solaiman O., Al-Aithan A.M., Al-Raddadi R., Ragab A., Balkhy H.H., Al Harthy A., Deeb A.M., Al Mutairi H., Al-Dawood A., Merson L., Hayden F.G., Fowler R.A., Saudi Critical Care Trial G. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am. J. Respir. Crit. Care Med. 2018;197(6):757\u2013767.","DOI":"10.1164\/rccm.201706-1172OC"},{"key":"4825_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032280","author":"K Kudo","year":"2012","unstructured":"Kudo K, Takasaki J, Manabe T, Uryu H, Yamada R, Kuroda E, Kobayashi N, Matsushita T (2012) Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0032280","journal-title":"PLoS ONE"},{"issue":"7","key":"4825_CR40","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1111\/ajt.15905","volume":"20","author":"A Romanelli","year":"2020","unstructured":"Romanelli A, Mascolo S (2020) Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: a therapeutical hypothesis. Am J Transplant 20(7):1947\u20131948","journal-title":"Am J Transplant"},{"issue":"1","key":"4825_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/a-1300-2550","volume":"53","author":"VI Alexaki","year":"2021","unstructured":"Alexaki VI, Henneicke H (2021) The role of glucocorticoids in the management of COVID-19. Horm Metab Res 53(1):9\u201315","journal-title":"Horm Metab Res"},{"key":"4825_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1096\/fj.01-0245com","volume":"16","author":"J Galon","year":"2002","unstructured":"Galon J, Franchimont D, Hiroi N et al (2002) Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 16:61\u201371","journal-title":"FASEB J"},{"issue":"2","key":"4825_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11739-021-02860-3","volume":"17","author":"R Sarzani","year":"2022","unstructured":"Sarzani R, Spannella F, Giulietti F, Di Pentima C, Giordano P, Giacometti A (2022) Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence. Intern Emerg Med 17(2):329\u2013338. https:\/\/doi.org\/10.1007\/s11739-021-02860-3","journal-title":"Intern Emerg Med"},{"key":"4825_CR44","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","volume":"10","author":"C Strehl","year":"2019","unstructured":"Strehl C, Ehlers L, Gaber T et al (2019) Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol 10:1744","journal-title":"Front Immunol"},{"issue":"4","key":"4825_CR45","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17(4):233\u2013247","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"4825_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1582-4934.2004.tb00321.x","volume":"8","author":"J Kountouras","year":"2004","unstructured":"Kountouras J, Zavos C, Chatzopoulos D (2004) Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med 8(3):317\u2013328","journal-title":"J Cell Mol Med"},{"key":"4825_CR47","doi-asserted-by":"crossref","unstructured":"Russell G, Graveley R, Seid J, et al. Mechanisms of action of cyclosporine and effects on connective tissues. InSeminars in arthritis and rheumatism 1992 Jun 1 [Vol. 21, No. 6, pp. 16\u201322].","DOI":"10.1016\/0049-0172(92)90009-3"},{"key":"4825_CR48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0162-3109(00)00192-","volume":"47","author":"S Matsuda","year":"2000","unstructured":"Matsuda S, Koyasu S (2000) Mechanisms of action of cyclosporine. Immunopharmacology 47:119\u2013125. https:\/\/doi.org\/10.1016\/s0162-3109(00)00192-","journal-title":"Immunopharmacology"},{"issue":"8","key":"4825_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/biology9080192","volume":"9","author":"P Glowacka","year":"2020","unstructured":"Glowacka P, Rudnicka L, Warszawik-Hendzel O, Sikora M, Goldust M, Gajda P, Stochmal A, Blicharz L, Rakowska A, Olszewska M (2020) The antiviral properties of cyclosporine. Focus on coronavirus, hepatitis C virus, influenza virus, and human immunodeficiency virus infections. Biology (Basel) 9(8):192. https:\/\/doi.org\/10.3390\/biology9080192","journal-title":"Biology (Basel)"},{"key":"4825_CR50","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.034983-0","author":"AH Wilde","year":"2011","unstructured":"Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, Thiel V, Narayanan K, Makino S, Snijder EJ, van Hemert MJ (2011) Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. https:\/\/doi.org\/10.1099\/vir.0.034983-0","journal-title":"J Gen Virol"},{"key":"4825_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01504-21","author":"C Fenizia","year":"2022","unstructured":"Fenizia C, Galbiati S, Vanetti C, Vago R, Clerici M, Tacchetti C, Daniele T (2022) Cyclosporine a inhibits viral infection and release as well as cytokine production in lung cells by three SARS-CoV-2 variants. Microbiol Spectr. https:\/\/doi.org\/10.1128\/spectrum.01504-21","journal-title":"Microbiol Spectr"},{"key":"4825_CR52","unstructured":"Williams JW, Xiao F, Foster PF, et al. Immunosuppressive effects of leflunomide in a cardiac allograft model. InTransplantation proceedings 1993 [Vol. 25, No. 1, pp. 745\u2013746]."},{"key":"4825_CR53","unstructured":"Kuchie CA, Thoenes GH, Langer KH, et al Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. In Transplantation proceedings 1991 [Vol. 23, No. 1, pp. 1083\u20131086]."},{"issue":"3","key":"4825_CR54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/s101650200034","volume":"12","author":"P Dimitrova","year":"2002","unstructured":"Dimitrova P, Kalden JR, Schulze-Koops H (2002) Leflunomide: an immunosuppressive drug with multiple effects on T cell function. Mod Rheumatol 12(3):195\u2013200","journal-title":"Mod Rheumatol"},{"issue":"7","key":"4825_CR55","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/1744666X.2019.1624527","volume":"15","author":"EH Van der Heijden","year":"2019","unstructured":"Van der Heijden EH, Hartgring SA et al (2019) Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sj\u00f6gren\u2019s syndrome. Expert Rev Clin Immunol 15(7):801\u2013808","journal-title":"Expert Rev Clin Immunol"},{"key":"4825_CR56","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2017.00407","volume":"8","author":"JI Moliva","year":"2017","unstructured":"Moliva JI, Turner J, Torrelles JB (2017) Immune responses to bacillus Calmette-Gu\u00e9rin vaccination: why do they fail to protect against Mycobacterium tuberculosis? Front Immunol 8:407","journal-title":"Front Immunol"},{"key":"4825_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011937","author":"SW Read","year":"2010","unstructured":"Read SW, DeGrezia M, Ciccone EJ, DerSimonian R, Higgins J, Adelsberger JW, Starling JM, Rehm C, Sereti I (2010) The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0011937","journal-title":"PLoS ONE"},{"key":"4825_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107398","author":"RD Alamri","year":"2021","unstructured":"Alamri RD, Elmeligy MA, Albalawi GA, Alquayr SM, Alsubhi SS, El-Ghaiesh SH (2021) Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review. Int Immunopharmacol. https:\/\/doi.org\/10.1016\/j.intimp.2021.107398","journal-title":"Int Immunopharmacol"},{"key":"4825_CR59","unstructured":"M. Millis, L. Perea, Leflunomide in Mild COVID-19 Patients. In.: https:\/\/ClinicalTrials.gov\/show\/NCT04361214, 2020"},{"issue":"2","key":"4825_CR60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0014-5793(93)81704-4","volume":"334","author":"T Mattar","year":"1993","unstructured":"Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A (1993) Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 334(2):161\u2013164","journal-title":"FEBS Lett"},{"issue":"2","key":"4825_CR61","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1399-3062.2011.00682.x","volume":"14","author":"B Chacko","year":"2012","unstructured":"Chacko B, John GT (2012) Leflunomide for cytomegalovirus: bench to bedside. Transplant Infect Dis. 14(2):111\u2013120","journal-title":"Transplant Infect Dis."},{"key":"4825_CR62","doi-asserted-by":"publisher","unstructured":"Pandey S, Cabot PJ, Shaw PN, Hewavitharana AK. Anti-inflammatory and immunomodulatory properties of Carica papaya. J Immunotoxicol. 2016 ;13(4):590\u2013602. doi: https:\/\/doi.org\/10.3109\/1547691X.2016.1149528. Epub 2016 Jul 14. PMID: 27416522 and documented to be effective against dengue virus","DOI":"10.3109\/1547691X.2016.1149528"},{"issue":"4","key":"4825_CR63","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S2221-1691(11)60055-5","volume":"1","author":"N Ahmad","year":"2011","unstructured":"Ahmad N, Fazal H, Ayaz M, Abbasi BH, Mohammad I, Fazal L (2011) Dengue fever treatment with Carica papaya leaves extracts. Asian Pac J Trop Biomed 1(4):330\u2013333. https:\/\/doi.org\/10.1016\/S2221-1691(11)60055-5","journal-title":"Asian Pac J Trop Biomed"},{"key":"4825_CR64","doi-asserted-by":"crossref","unstructured":"Lalani S, Poh CL. Flavonoids as antiviral agents for Enterovirus A71 [EV-A71]. Viruses. 2020; 12[2]:184.","DOI":"10.3390\/v12020184"},{"key":"4825_CR65","doi-asserted-by":"crossref","unstructured":"Mendes LF, Gaspar VM, Conde TA, et al. Flavonoid-mediated immunomodulation of human macrophages involves key metabolites and metabolic pathways. Sci Rep. 2019; 9[1]:1.","DOI":"10.1038\/s41598-019-51113-z"},{"issue":"4","key":"4825_CR66","first-page":"673","volume":"52","author":"E Middleton","year":"2000","unstructured":"Middleton E, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52(4):673\u2013751","journal-title":"Pharmacol Rev"},{"issue":"2","key":"4825_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4162\/nrp.2015.9.2.137","volume":"9","author":"X Sun","year":"2015","unstructured":"Sun X, Yamasaki M, Katsube T et al (2015) Effects of quercetin derivatives from mulberry leaves: Improved gene expression related hepatic lipid and glucose metabolism in short-term high-fat fed mice. Nutr Res Pract 9(2):137\u2013143","journal-title":"Nutr Res Pract"},{"key":"4825_CR68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4615-5335-9_13","volume":"439","author":"E Middleton Jr","year":"1998","unstructured":"Middleton E Jr (1998) Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol 439:175\u2013182. https:\/\/doi.org\/10.1007\/978-1-4615-5335-9_13","journal-title":"Adv Exp Med Biol"},{"key":"4825_CR69","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fimmu.2019.00051","volume":"10","author":"A Hosseinzade","year":"2019","unstructured":"Hosseinzade A, Sadeghi O, Naghdipour Biregani A et al (2019) Immunomodulatory effects of flavonoids: possible induction of T CD4+ regulatory cells through suppression of mTOR pathway signaling activity. Front Immunol 10:51","journal-title":"Front Immunol"},{"issue":"2","key":"4825_CR70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0162-3109(82)90015-7","volume":"4","author":"A Schwartz","year":"1982","unstructured":"Schwartz A, Sutton SL, Middleton E Jr (1982) Quercetin inhibition of the induction and function of cytotoxic T lymphocytes. Immunopharmacol 4(2):125\u2013138","journal-title":"Immunopharmacol"},{"issue":"4","key":"4825_CR71","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.phrs.2009.10.005","volume":"61","author":"AP Rogerio","year":"2010","unstructured":"Rogerio AP, Dora CL, Andrade EL, Chaves JS, Silva LF, Lemos-Senna E, Calixto JB (2010) Anti-inflammatory effect of quercetin-loaded microemulsion in the airways allergic inflammatory model in mice. Pharmacol Res 61(4):288\u2013297","journal-title":"Pharmacol Res"},{"issue":"4","key":"4825_CR72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/187152810793358741","volume":"9","author":"S Chirumbolo","year":"2010","unstructured":"Chirumbolo S (2010) The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm Allergy Drug Targets 9(4):263\u2013285","journal-title":"Inflamm Allergy Drug Targets"},{"key":"4825_CR73","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.1021\/jf903698s","volume":"58","author":"KM Lee","year":"2010","unstructured":"Lee KM, Hwang MK, Lee DE, Lee KW, Lee HJ (2010) Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. J Agric Food Chem 58:5815\u20135820","journal-title":"J Agric Food Chem"},{"issue":"3","key":"4825_CR74","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/nu8030167","volume":"8","author":"Y Li","year":"2016","unstructured":"Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, Liu H, Yin Y (2016) Quercetin, Inflammation and Immunity. Nutrients 8(3):167","journal-title":"Nutrients"},{"issue":"3","key":"4825_CR75","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/molecules28030938","volume":"28","author":"FM Doishorobi","year":"2023","unstructured":"Doishorobi FM, Nisa FY, Saha S, Chowdhury MAH, Srisuphanunt M, Hossain KH, Rahman MA (2023) Quercetin: a functional food-flavonoid incredibly attenuates emerging and re-emerging viral infections through immunomodulatory actions. Molecules 28(3):938. https:\/\/doi.org\/10.3390\/molecules28030938","journal-title":"Molecules"},{"key":"4825_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109800","volume":"142","author":"JJ DiNicolantonio","year":"2020","unstructured":"DiNicolantonio JJ, McCarty MF (2020) Targeting Casein kinase 2 with quercetin or enzymatically modified isoquercitrin as a strategy for boosting the type 1 interferon response to viruses and promoting cardiovascular health. Med Hypotheses 142:109800","journal-title":"Med Hypotheses"},{"key":"4825_CR77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.virusres.2015.01.018","volume":"200","author":"N Komaravelli","year":"2015","unstructured":"Komaravelli N, Kelley JP, Garofalo MP, Wu H, Casola A, Kolli D (2015) Role of dietary antioxidants in human metapneumovirus infection. Virus Res 200:19\u201323","journal-title":"Virus Res"},{"key":"4825_CR78","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.2147\/IJGM.S318720","volume":"14","author":"F Di Pierro","year":"2021","unstructured":"Di Pierro F, Derosa G, Maffioli P, Bertuccioli A, Togni S, Riva A, Allegrini P, Khan A, Khan S, Khan BA et al (2021) Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study. Int J Gen Med 14:2359\u20132366","journal-title":"Int J Gen Med"},{"key":"4825_CR79","doi-asserted-by":"crossref","unstructured":"Te Velthuis, A.J.; Fodor, E. Influenza virus RNA polymerase: Insights into the mechanisms of viral RNA synthesis. Nat. Rev Microbiol. 2016, 14, 479\u2013493. [CrossRef] [PubMed]","DOI":"10.1038\/nrmicro.2016.87"},{"key":"4825_CR80","doi-asserted-by":"crossref","unstructured":"Parvez, M.K.; Rehman, T.; Alam, P.; Al-Dosari, M.S.; Alqasoumi, S.I.; Alajmi, M.F. Plant-derived antiviral drugs as novel hepatitisB virus inhibitors: Cell culture and molecular docking study. Saudi Pharm. J. 2018, 27, 389\u2013400. [CrossRef] [PubMed]","DOI":"10.1016\/j.jsps.2018.12.008"},{"key":"4825_CR81","doi-asserted-by":"crossref","unstructured":"Yang, X.; Zhu, X.; Ji, H.; Deng, J.; Lu, P.; Jiang, Z.; Li, X.;Wang, Y.;Wang, C.; Zhao, J.; et al. Quercetin synergistically reactivateshuman immunodeficiency virus type 1 latency by activating nuclear factor-_B. Mol. Med. Rep. 2017, 17, 2501\u20132508. [CrossRef]","DOI":"10.3892\/mmr.2017.8188"},{"key":"4825_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106339","volume":"9","author":"K Fatima","year":"2014","unstructured":"Fatima K, Mathew S, Suhail M, Ali A, Damanhouri G, Azhar E, Qadri I (2014) Docking studies of Pakistani HCV NS3 helicase: Apossible antiviral drug target. PLoS ONE 9:e106339","journal-title":"PLoS ONE"},{"key":"4825_CR83","doi-asserted-by":"crossref","unstructured":"Hung, P.-Y.; Ho, B.-C.; Lee, S.-Y.; Chang, S.-Y.; Kao, C.-L.; Lee, S.-S.; Lee, C.-N. Houttuynia cordata Targets the Beginning Stage ofHerpes Simplex Virus Infection. PLoS ONE 2015, 10, e0115475. [CrossRef] [PubMed].","DOI":"10.1371\/journal.pone.0115475"},{"issue":"1-2","key":"4825_CR84","first-page":"9","volume":"428","author":"HJ Liu","year":"2017","unstructured":"Liu HJ, Fan YL, Liao HH et al (2017) Apigenin alleviates STZ-induced diabetic cardiomyopathy. Mol Cell Bio chem 428(1\u20132):9\u201321","journal-title":"Mol Cell Bio chem"},{"issue":"1","key":"4825_CR85","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/aid.1996.12.39","volume":"12","author":"JW Critchfield","year":"1996","unstructured":"Critchfield JW, Butera ST, Folks TM (1996) Inhibition of HIV activation in latently infected cells by flavonoid compounds. AIDS Res Hum Retroviruses 12(1):39\u201346","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4825_CR86","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.virol.2014.05.024","volume":"462\u2013463","author":"C Shibata","year":"2014","unstructured":"Shibata C, Ohno M, Otsuka M, Kishikawa T, Goto K, Muroyama R, Kato N, Yoshikawa T, Takata A, Koike K (2014) The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology 462\u2013463:42\u201348. https:\/\/doi.org\/10.1016\/j.virol.2014.05.024. (Epub 2014 Jun 14 PMID: 25092460)","journal-title":"Virology"},{"key":"4825_CR87","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.antiviral.2014.06.004","volume":"109","author":"X Lv","year":"2014","unstructured":"Lv X, Qiu M, Chen D, Zheng N, Jin Y, Wu Z (2014) Apigenin inhibits enterovirus 71 replication through suppressing viral IRES activity and modulating cellular JNK pathway. Antiviral Res 109:30\u201341. https:\/\/doi.org\/10.1016\/j.antiviral.2014.06.004. (Epub 2014 Jun 24 PMID: 24971492)","journal-title":"Antiviral Res"},{"key":"4825_CR88","doi-asserted-by":"publisher","unstructured":"Zhang W, Qiao H, Lv Y, Wang J, Chen X, Hou Y, Tan R, Li E. Apigenin inhibits enterovirus-71 infection by disrupting viral RNA association with trans-acting factors. PLoS One. 2014 Oct 16;9(10):e110429. doi: https:\/\/doi.org\/10.1371\/journal.pone.0110429. PMID: 25330384; PMCID: PMC4199717.-","DOI":"10.1371\/journal.pone.0110429"},{"issue":"12","key":"4825_CR89","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/jmv.26403","volume":"92","author":".Xu X, Miao J, Shao Q, Gao Y, Hong","year":"2020","unstructured":".Xu X, Miao J, Shao Q, Gao Y, Hong L. (2020) Apigenin suppresses influenza A virus-induced RIG-I activation and viral replication. J Med Virol 92(12):3057\u20133066","journal-title":"J Med Virol"},{"key":"4825_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2023.03.016","volume":"583","author":"C Acchioni","year":"2023","unstructured":"Acchioni C, Acchioni M, Mancini F, Amendola A, Marsili G, Tirelli V, Gwee CP, Chan KW, Sandini S, Bisbocci M, Mysara M, ElHefnawi M, Sanchez M, Venturi G, Barreca ML, Manfroni G, Bresciani A, Vasudevan SG, Sgarbanti M (2023) A cellular screening platform, stably expressing DENV2 NS5, defines a novel anti-DENV mechanism of action of Apigenin based on STAT2 activation. Virology 583:1\u201313. https:\/\/doi.org\/10.1016\/j.virol.2023.03.016. (Epub 2023 Apr 5 PMID: 37060797)","journal-title":"Virology"},{"key":"4825_CR91","doi-asserted-by":"publisher","unstructured":"bdizadeh R, Hadizadeh F, Abdizadeh T. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies. J BiomolStructDyn. 2022. doi: https:\/\/doi.org\/10.1080\/07391102.2022.2098821","DOI":"10.1080\/07391102.2022.2098821"},{"key":"4825_CR92","doi-asserted-by":"crossref","unstructured":"Cardenas H, Arango D, Nicholas C, Duarte S, Nuovo GJ, He W, et al. Dietary apigenin exerts immune-regulatory activity in vivo by reducing NF-\u03baB activity, halting leukocyte infiltration and restoring normal metabolic function. Int J Mol Sci. 2016;17[3]:323.","DOI":"10.3390\/ijms17030323"},{"issue":"6","key":"4825_CR93","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s10753-014-9942-x","volume":"37","author":"J Wang","year":"2014","unstructured":"Wang J, Liu YT, Xiao L, Zhu L et al (2014) Anti-inflammatory effects of apigenin in lipopolysaccharide-induced inflammatory in acute lung injury by suppressing COX-2 and NF-kB pathway. Inflammation 37(6):2085\u20132090","journal-title":"Inflammation"},{"issue":"1","key":"4825_CR94","first-page":"17","volume":"13","author":"DN Che","year":"2014","unstructured":"Che DN, Cho BO, Shin JY, Kang HJ, Kim Shukla S, Bajpai VK, Kim M (2014) Plants as potential sources of natural immunomodulators. Rev Environ SciBiotechnol 13(1):17\u201333","journal-title":"Rev Environ SciBiotechnol"},{"issue":"3","key":"4825_CR95","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0934-8840(11)80686-9","volume":"274","author":"W Roszkowski","year":"1990","unstructured":"Roszkowski W, Roszkowski K, Ko HL et al (1990) Immunomodulation by propionibacteria. Zentralblatt f\u00fcr Bakteriologie 274(3):289\u2013298","journal-title":"Zentralblatt f\u00fcr Bakteriologie"},{"issue":"11","key":"4825_CR96","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0192-0561(00)00044-8","volume":"22","author":"S Marinova","year":"2000","unstructured":"Marinova S, Tchorbadjiiska L, Petrunov B et al (2000) Immunostimulating and protective effects of an oral polybacterial immunomodulator \u2018Dentavax\u2019in a rabbit experimental model. Int J Immunopharmacol 22(11):843\u2013854","journal-title":"Int J Immunopharmacol"},{"key":"4825_CR97","doi-asserted-by":"crossref","unstructured":"Talib WH, Saleh S. Propionibacterium acnes augments antitumor, anti-angiogenesis and immunomodulatory effects of melatonin on breast cancer implanted in mice. PloS one. 2015;10[4]:e0124384.","DOI":"10.1371\/journal.pone.0124384"},{"key":"4825_CR98","doi-asserted-by":"publisher","unstructured":"Frediansyah, A.; Sofyantoro, F.; Alhumaid, S.; Al Mutair, A.; Albayat, H.; Altaweil, H.I.; Al-Afghani, H.M.; AlRamadhan, A.A.; AlGhazal, M.R.; Turkistani, S.A.; Abuzaid, A.A.; Rabaan, A.A. Microbial natural products with antiviral activities, including anti-SARS-CoV-2: a review.\u00a0Molecules\u00a02022,\u00a027, 4305. https:\/\/doi.org\/10.3390\/molecules27134305","DOI":"10.3390\/molecules27134305"},{"issue":"4","key":"4825_CR99","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2672.2004.02353.x","volume":"97","author":"CM Galdeano","year":"2004","unstructured":"Galdeano CM, Perdigon G (2004) Role of viability of probiotic strains in their persistence in the gut and in mucosal immune stimulation. J Appl Microbiol 97(4):673\u2013681","journal-title":"J Appl Microbiol"},{"issue":"2\u20133","key":"4825_CR100","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijfoodmicro.2010.04.007","volume":"140","author":"B Folign\u00e9","year":"2010","unstructured":"Folign\u00e9 B, Dewulf J, Breton J et al (2010) Probiotic properties of non-conventional lactic acid bacteria: immunomodulation by Oenococcus oeni. Int J Food Microbiol 140(2\u20133):136\u2013145","journal-title":"Int J Food Microbiol"},{"issue":"1","key":"4825_CR101","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2174\/187221309787158461","volume":"3","author":"P Bodera","year":"2009","unstructured":"Bodera P, Chcialowski A (2009) Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov 3(1):58\u201364","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"4825_CR102","first-page":"1","volume":"2018","author":"M Azad","year":"2018","unstructured":"Azad M, Kalam A, Sarker M et al (2018) Probiotic species in the modulation of gut microbiota: an overview. BioMed Res Int 2018:1\u20138","journal-title":"BioMed Res Int"},{"key":"4825_CR103","doi-asserted-by":"publisher","unstructured":"Jounai K, Sugimura T, Ohshio K, et al. Oral administration of Lactococcus lactis subsp. lactis JCM5805 enhances lung immune response resulting in protection from murine parainfluenza virus infection. PloS one. 2015; doi: https:\/\/doi.org\/10.1371\/journal.pone.0119055","DOI":"10.1371\/journal.pone.0119055"},{"issue":"5","key":"4825_CR104","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrmicro1840","volume":"6","author":"JM Wells","year":"2008","unstructured":"Wells JM, Mercenier A (2008) Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6(5):349\u2013362","journal-title":"Nat Rev Microbiol"},{"key":"4825_CR105","doi-asserted-by":"crossref","unstructured":"Rosenberg H F., B Domachowske J. Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics. Curr Med Chem. 2012;19:1424\u20131431.","DOI":"10.2174\/092986712799828346"},{"key":"4825_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00186","author":"D Baud","year":"2020","unstructured":"Baud D, Agri VD, Gibson GR, Reid G, Giannoni E (2020) Using probiotics to flatten the curve of coronavirus disease COVID-2019 pandemic. Front Public Health. https:\/\/doi.org\/10.3389\/fpubh.2020.00186","journal-title":"Front Public Health"},{"key":"4825_CR107","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.intimp.2010.11.019","volume":"11","author":"N Kobayashi","year":"2011","unstructured":"Kobayashi N, Saito T, Uematsu T, Kishi K, Toba M, Kohda N, Suzuki T (2011) Oral administration of heat-killed Lactobacillus pentosus strain b240 augments protection against influenza virus infection in mice. Int Immunopharmacol 11:199\u2013203","journal-title":"Int Immunopharmacol"},{"key":"4825_CR108","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1128\/CDLI.6.2.186-192.1999","volume":"6","author":"H Yasui","year":"1999","unstructured":"Yasui H, Kiyoshima J, Hori T, Shida K (1999) Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol 6:186\u2013192","journal-title":"Clin Diagn Lab Immunol"},{"key":"4825_CR109","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/426028","volume":"2014","author":"Q Jiao","year":"2014","unstructured":"Jiao Q, Li L, Mu Q, Zhang Q (2014) Immunomodulation of nanoparticles in nanomedicine applications. Biomed Res Int 2014:426028","journal-title":"Biomed Res Int"},{"issue":"6","key":"4825_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11051-013-1711-5","volume":"15","author":"M De Nicola","year":"2013","unstructured":"De Nicola M, Gattia DM, Traversa E et al (2013) Maturation and demise of human primary monocytes by carbon nanotubes. J Nanopart Res 15(6):1\u20135","journal-title":"J Nanopart Res"},{"issue":"1","key":"4825_CR111","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1109\/TNB.2009.2016550","volume":"8","author":"A Hoshino","year":"2009","unstructured":"Hoshino A, Hanada S, Manabe N (2009) Immune response induced by fluorescent nanocrystal quantum dots in vitro and in vivo. IEEE Trans Nano Biosci 8(1):51\u201357","journal-title":"IEEE Trans Nano Biosci"},{"issue":"9","key":"4825_CR112","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.biomaterials.2006.12.003","volume":"28","author":"K M\u00fcller","year":"2007","unstructured":"M\u00fcller K, Skepper JN, Posfai M et al (2007) Effect of ultrasmallsuperparamagnetic iron oxide nanoparticles [Ferumoxtran-10] on human monocyte-macrophages in vitro. Biomaterials 28(9):1629\u20131642","journal-title":"Biomaterials"},{"key":"4825_CR113","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.2147\/IJN.S31054","volume":"7","author":"CC Shen","year":"2012","unstructured":"Shen CC, Liang HJ, Wang CC, Liao MH, Jan TR (2012) Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. Int J Nanomedicine 7:2729\u20132737. https:\/\/doi.org\/10.2147\/IJN.S31054","journal-title":"Int J Nanomedicine"},{"key":"4825_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201604139","author":"MS Draz","year":"2017","unstructured":"Draz MS, Wang YJ, Chen FF, Xu Y, Shafiee H (2017) Electrically oscillating plasmonic nanoparticles for enhanced DNA vaccination against hepatitis C virus. Adv Funct Mater. https:\/\/doi.org\/10.1002\/adfm.201604139","journal-title":"Adv Funct Mater"},{"issue":"1","key":"4825_CR115","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/nnm-2016-0306","volume":"12","author":"M Vetro","year":"2017","unstructured":"Vetro M, Safari D, Fallarini S, Salsabila K, Lahmann M, Penad\u00e9s S, Lay L, Marradi M, Compostella F (2017) Preparation and immunogenicity of gold glyco-nanoparticles as antipneumococcal vaccine model. Nanomedicine (Lond) 12(1):13\u201323. https:\/\/doi.org\/10.2217\/nnm-2016-0306","journal-title":"Nanomedicine (Lond)"},{"issue":"2","key":"4825_CR116","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1039\/c5nh00064e","volume":"1","author":"Y Liu","year":"2016","unstructured":"Liu Y, Wang H, Li D, Tian Y, Liu W, Zhang L, Zheng W, Hao Y, Liu J, Yang Z, Shao Y, Jiang X (2016) In situ formation of peptidic nanofibers can fundamentally optimize the quality of immune responses against HIV vaccine. Nanoscale Horiz 1(2):135\u2013143. https:\/\/doi.org\/10.1039\/c5nh00064e","journal-title":"Nanoscale Horiz"},{"issue":"1","key":"4825_CR117","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41467-017-02725-4","volume":"9","author":"L Deng","year":"2018","unstructured":"Deng L, Mohan T, Chang TZ, Gonzalez GX, Wang Y, Kwon YM, Kang SM, Compans RW, Champion JA, Wang BZ (2018) Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Nat Commun 9(1):359. https:\/\/doi.org\/10.1038\/s41467-017-02725-4","journal-title":"Nat Commun"},{"key":"4825_CR118","doi-asserted-by":"publisher","first-page":"44839","DOI":"10.1038\/srep44839","volume":"7","author":"J Yang","year":"2017","unstructured":"Yang J, Shim SM, Nguyen TQ, Kim EH, Kim K, Lim YT, Sung MH, Webby R, Poo H (2017) Poly-\u03b3-glutamic acid\/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine. Sci Rep 7:44839. https:\/\/doi.org\/10.1038\/srep44839","journal-title":"Sci Rep"},{"key":"4825_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201900101","author":"X Feng","year":"2019","unstructured":"Feng X, Xu W, Li Z, Song W, Ding J, Chen X (2019) Immunomodulatory Nanosystems. Adv Sci (Weinh). https:\/\/doi.org\/10.1002\/advs.201900101","journal-title":"Adv Sci (Weinh)"},{"key":"4825_CR120","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00903-20","volume":"11","author":"G Zhang","year":"2020","unstructured":"Zhang G, Campbell GR, Zhang Q, Maule E, Hanna J, Gao W, Zhang L, Spector SA (2020) CD4+ t cell-mimicking nanoparticles broadly neutralize hiv-1 and suppress viral replication through autophagy. MBio 11:e45","journal-title":"MBio"},{"key":"4825_CR121","doi-asserted-by":"crossref","unstructured":"Morris D, Ansar M, Speshock J, et al. Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection. Viruses. 2019 ;11[8]:732.","DOI":"10.3390\/v11080732"},{"key":"4825_CR122","doi-asserted-by":"publisher","unstructured":"Kumar NG, Contaifer D, Madurantakam P, et al Dietary bioactive fatty acids as modulators of immune function: implications on human health. Nutrients. 2019;11:2974. doi: https:\/\/doi.org\/10.3390\/nu11122974","DOI":"10.3390\/nu11122974"},{"key":"4825_CR123","doi-asserted-by":"crossref","unstructured":"Parnham MJ, Englberger W. Lipid mediators and lymphocyte function. In: Michael A. Bray, John Morley (Eds) The Pharmacology of Lymphocytes 1988 [pp. 385\u2013414]. Springer, Berlin Heidelberg.","DOI":"10.1007\/978-3-642-73217-1_16"},{"issue":"12","key":"4825_CR124","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1093\/jn\/132.12.3566","volume":"132","author":"M Anderson","year":"2002","unstructured":"Anderson M, Fritsche KL (2002) [n-3] Fatty acids and infectious disease resistance. J Nutr 132(12):3566\u20133576","journal-title":"J Nutr"},{"issue":"10","key":"4825_CR125","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.nut.2009.02.010","volume":"25","author":"H Shapiro","year":"2009","unstructured":"Shapiro H, Lev S, Cohen J et al (2009) Polyphenols in the prevention and treatment of sepsis syndromes: rationale and pre-clinical evidence. Nutrition 25(10):981\u2013997","journal-title":"Nutrition"},{"issue":"4-6","key":"4825_CR126","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.plefa.2010.02.023","volume":"82","author":"NA Khan","year":"2010","unstructured":"Khan NA (2010) Polyunsaturated fatty acids in the modulation of T-cell signalling. Prostaglandins Leukot Essent Fatty Acids 82(4\u20136):179\u2013187","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"6","key":"4825_CR127","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jinf.2016.10.001","volume":"73","author":"MO Husson","year":"2016","unstructured":"Husson MO, Ley D, Portal C et al (2016) Modulation of host defence against bacterial and viral infections by omega-3 polyunsaturated fatty acids. J Infect 73(6):523\u2013535. https:\/\/doi.org\/10.1016\/j.jinf.2016.10.001","journal-title":"J Infect"},{"issue":"4","key":"4825_CR128","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrmicro2745","volume":"10","author":"RE Hancock","year":"2012","unstructured":"Hancock RE, Nijnik A, Philpott DJ (2012) Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 10(4):243\u2013254","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"4825_CR129","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.mib.2013.06.011","volume":"16","author":"A Nijnik","year":"2013","unstructured":"Nijnik A (2013) Immunomodulatory approaches for prevention and treatment of infectious diseases. Curr Opin Microbiol 16(5):590\u2013595","journal-title":"Curr Opin Microbiol"},{"issue":"4","key":"4825_CR130","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1517\/14712598.1.4.641","volume":"1","author":"KN Masihi","year":"2001","unstructured":"Masihi KN (2001) Fighting infection using immunomodulatory agents. Expert Opin Biol Ther 1(4):641\u2013653","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"4825_CR131","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.nut.2009.02.010","volume":"25","author":"H Shapiro","year":"2009","unstructured":"Shapiro H, Lev S, Cohen J, Singer P (2009) Polyphenols in the prevention and treatment of sepsis syndromes: rationale and pre-clinical evidence. Nutrition 25(10):981\u2013997","journal-title":"Nutrition"},{"key":"4825_CR132","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-3139-2_9","volume":"1371","author":"SW Tas","year":"2016","unstructured":"Tas SW, Baeten DL (2016) Recent advances in the treatment of immune-mediated inflammatory diseases. Methods Mol Biol 1371:143\u2013155","journal-title":"Methods Mol Biol"},{"key":"4825_CR133","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms20205023","volume":"20","author":"Y Bedoui","year":"2020","unstructured":"Bedoui Y, Guillot X, S\u00e9lambarom J et al (2020) Methotrexate an old drug with new tricks. J Mol Sci 20:5023","journal-title":"J Mol Sci"},{"key":"4825_CR134","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coi.2018.04.011","volume":"53","author":"A Casadevall","year":"2018","unstructured":"Casadevall A (2018) Antibody-based vaccine strategies against intracellular pathogens. Curr Opin Immunol 53:74\u201380","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"4825_CR135","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/bja\/aep128","volume":"103","author":"NR Webster","year":"2009","unstructured":"Webster NR, Galley HF (2009) Immunomodulation in the critically ill. Br J Anaesth 103(1):70\u201381","journal-title":"Br J Anaesth"},{"key":"4825_CR136","unstructured":"National Research Council [US] Committee on New Directions in the Study of Antimicrobial Therapeutics: New Classes of Antimicrobials; National Research Council [US] Committee on New Directions in the Study of Antimicrobial Therapeutics: Immunomodulation.\u00a0Treating Infectious Diseases in a Microbial World: Report of Two Workshops on Novel Antimicrobial Therapeutics. Washington, DC: National Academies Press [US]"},{"key":"4825_CR137","first-page":"1","volume":"21","author":"JG Rizk","year":"2020","unstructured":"Rizk JG, Kalantar-Zadeh K, Mehra MR et al (2020) Pharmaco-immunomodulatory therapy in COVID-19. Drugs 21:1\u201326","journal-title":"Drugs"},{"issue":"12","key":"4825_CR138","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0192-0561(00)00074-6","volume":"22","author":"KN Masihi","year":"2000","unstructured":"Masihi KN (2000) Immunomodulators in infectious diseases: panoply of possibilites. IntImmunopharmacol 22(12):1083\u20131091","journal-title":"IntImmunopharmacol"},{"issue":"2 Suppl 2","key":"4825_CR139","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.1016\/j.jaci.2009.08.018","volume":"125","author":"SJ Lee","year":"2010","unstructured":"Lee SJ, Chinen J, Kavanaugh A (2010) Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. J Allergy Clin Immunol 125(2 Suppl 2):S314\u2013S323","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"4825_CR140","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cmi.2018.04.024","volume":"25","author":"E Pelfrene","year":"2019","unstructured":"Pelfrene E, Mura M, Sanches AC et al (2019) Monoclonal antibodies as anti-infective products: a promising future? Clin Microbiol Infect 25(1):60\u201364","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"4825_CR141","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00148581-200406030-00004","volume":"6","author":"C Fenton","year":"2004","unstructured":"Fenton C, Scott LJ, Plosker GL (2004) Palivizumab. Paediatr Drugs 6(3):177\u2013197","journal-title":"Paediatr Drugs"},{"key":"4825_CR142","doi-asserted-by":"crossref","unstructured":"Mej\u00edas A, Ch\u00e1vez-Bueno S, R\u00edos AM, et al. Anti-respiratory syncytial virus [RSV] neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother. 2004;48[5]:1811-","DOI":"10.1128\/AAC.48.5.1811-1822.2004"},{"key":"4825_CR143","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3389\/fmicb.2017.02323","volume":"8","author":"SA Jacob","year":"2017","unstructured":"Jacob SA, Iacob DG (2017) Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. Front microbiol 8:2323","journal-title":"Front microbiol"},{"key":"4825_CR144","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1086\/430708","volume":"41","author":"GM Subramanian","year":"2005","unstructured":"Subramanian GM, Cronin PW, Poley G et al (2005) A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 41:12\u201320","journal-title":"Clin Infect Dis"},{"key":"4825_CR145","unstructured":"U.S. Food and Drug Administration. Coronavirus COVID-19 Update FDA Authorizes Monoclonal Antibodies Treatment COVID-19]. Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fdaauthorizes-monoclonal-antibodies-treatment-covid-19"},{"key":"4825_CR146","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1086\/500143","volume":"193","author":"A Roberts","year":"2006","unstructured":"Roberts A, Thomas WD, Guarner J et al (2006) Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis 193:685\u2013692","journal-title":"J Infect Dis"},{"key":"4825_CR147","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1086\/503428","volume":"42","author":"J Pachl","year":"2006","unstructured":"Pachl J, Svoboda P, Jacobs F et al (2006) A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42:1404\u20131413","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4825_CR148","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1566524054022594","volume":"5","author":"RC Matthews","year":"2005","unstructured":"Matthews RC, Burnie JP (2005) Human recombinant antibody to HSP90: a natural partner in combination therapy. Curr Mol Med 5(4):403\u2013411","journal-title":"Curr Mol Med"},{"key":"4825_CR149","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.drudis.2015.10.012","volume":"21","author":"F Bootz","year":"2016","unstructured":"Bootz F, Neri D (2016) Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today 21:180\u2013218","journal-title":"Drug Discov Today"},{"key":"4825_CR150","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/emmm.201303131","volume":"6","author":"CM Lange","year":"2014","unstructured":"Lange CM, Jacobson IM, Rice CM, Zeuzem S (2014) Emerging therapies for the treatment of hepatitis C. EMBO Mol Med 6:4","journal-title":"EMBO Mol Med"},{"key":"4825_CR151","unstructured":"Ferreira VL, Borba HH, Bonetti AF, et al. Cytokines and Interferons: Types and Functions, Autoantibodies and Cytokines. Wahid Ali Khan: Intech Open. 2018"},{"key":"4825_CR152","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.antiviral.2015.07.006","volume":"121","author":"J Chang","year":"2015","unstructured":"Chang J, Guo JT (2015) Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure. Antiviral Res 121:152\u2013159","journal-title":"Antiviral Res"},{"key":"4825_CR153","first-page":"2853","volume":"21","author":"J Manishi","year":"1994","unstructured":"Manishi J (1994) Interferon-alpha, beta, gamma. Gan to kagakuryoho. Cancer Chemother 21:2853","journal-title":"Cancer Chemother"},{"issue":"4","key":"4825_CR154","first-page":"723","volume":"25","author":"KN Masihi","year":"2011","unstructured":"Masihi KN, Sch\u00e4fer H (2011) Overview of biologic response modifiers in infectious disease. Infect Dis Clin 25(4):723\u2013731","journal-title":"Infect Dis Clin"},{"key":"4825_CR155","first-page":"323","volume":"2010","author":"RM Friedman","year":"2010","unstructured":"Friedman RM, Contente S (2010) Treatment of hepatitis C infections with interferon: a historical perspective. Hepat Res Treat. 2010:323\u2013326","journal-title":"Hepat Res Treat."},{"key":"4825_CR156","first-page":"52","volume":"11","author":"\u00d6 Stranneg\u00e5rd","year":"1999","unstructured":"Stranneg\u00e5rd \u00d6 (1999) Interferons and their therapeutic applications. EJIFCC 11:52","journal-title":"EJIFCC"},{"key":"4825_CR157","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/iai.56.8.2011-2015.1988","volume":"56","author":"A Nakane","year":"1988","unstructured":"Nakane A, Minagawa T, Yasuda I et al (1988) Prevention by gamma interferon of fatal infection with Listeria monocytogenes infection. Infect Immun 56:2011\u20132015","journal-title":"Infect Immun"},{"key":"4825_CR158","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1128\/iai.60.1.84-89.1992","volume":"60","author":"DA Leiby","year":"1992","unstructured":"Leiby DA, Fortier AH, Crawford RM et al (1992) In vivo modulation of the murine immune response to Francisellatularensis LVS by administration of anticytokine antibodies. Infect Immun 60:84\u201389","journal-title":"Infect Immun"},{"issue":"2","key":"4825_CR159","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/BF01964408","volume":"10","author":"CS Subauste","year":"1991","unstructured":"Subauste CS, Remington JS (1991) Role of gamma interferon in Toxoplasma gondii infection. Eur J Clin Microbiol Infect Dis 10(2):58\u201367","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4825_CR160","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1128\/iai.59.11.3859-3862.1991","volume":"59","author":"JM Beck","year":"1991","unstructured":"Beck JM, Brunette EN, Fuchs HJ et al (1991) Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun 59:3859\u20133862","journal-title":"Infect Immun"},{"key":"4825_CR161","doi-asserted-by":"publisher","first-page":"762","DOI":"10.4049\/jimmunol.146.2.762","volume":"146","author":"LM Kumaratilake","year":"1991","unstructured":"Kumaratilake LM, Ferrante A, Rzepczyk C (1991) The role of T lymphocytes in immunity to Plasmodium falciparum. Enhancement of neutrophil-mediated parasite killing by lymhotoxin and IFN-gamma: comparisons with tumor necrosis factor effects. J Immunol 146:762\u2013767","journal-title":"J Immunol"},{"key":"4825_CR162","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1128\/iai.56.11.3004-3006.1988","volume":"56","author":"DM Williams","year":"1988","unstructured":"Williams DM, Byrne GI, Grubbs B et al (1988) Role in vivo for gamma interferon in control of pneumonia caused by Clamydia trachomatis. Infect Immun 56:3004\u20133006","journal-title":"Infect Immun"},{"key":"4825_CR163","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1128\/iai.55.5.1252-1255.1987","volume":"55","author":"H Li","year":"1987","unstructured":"Li H, Jerrells TR, Spitalny GL et al (1987) Gamma interferon as a crucial host defense against Rikettsiaconorii in vivo. Infect Immun 55:1252\u20131255","journal-title":"Infect Immun"},{"key":"4825_CR164","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1128\/IAI.66.2.800-806.1998","volume":"66","author":"LE Cano","year":"1998","unstructured":"Cano LE, Kashino SS, Arruda C et al (1998) Protective role of gamma interferon in experimental pulmonary paracoccidioidomycosis. Infect Immun 66:800\u2013806","journal-title":"Infect Immun"},{"key":"4825_CR165","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1128\/IAI.66.4.1342-1348.1998","volume":"66","author":"SS Way","year":"1998","unstructured":"Way SS, Borczuk AC, Dominitz R et al (1998) An essential role for gamma interferon in innate resistance to Shigellaflexneri infection. Infect Immun 66:1342\u20131348","journal-title":"Infect Immun"},{"key":"4825_CR166","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.3389\/fimmu.2019.03127","volume":"10","author":"Z Meng","year":"2020","unstructured":"Meng Z, Chen Y, Lu M (2020) Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection. Front Immunol 10:3127","journal-title":"Front Immunol"},{"issue":"1","key":"4825_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-7364-5-1-30","volume":"5","author":"C Brocker","year":"2010","unstructured":"Brocker C, Thompson D, Matsumoto A et al (2010) Evolutionary divergence and functions of the human interleukin [IL] gene family. Hum Genomics 5(1):1\u201326","journal-title":"Hum Genomics"},{"issue":"5","key":"4825_CR168","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","volume":"13","author":"B Oppmann","year":"2000","unstructured":"Oppmann B, Lesley R, Blom B et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13(5):715\u2013725","journal-title":"Immunity"},{"issue":"1","key":"4825_CR169","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/jlb.62.1.126","volume":"62","author":"LJ Montaner","year":"1997","unstructured":"Montaner LJ, Bailer RT, Gordon S (1997) IL-13 acts on macrophages to block the completion of reverse transcription, inhibit virus production, and reduce virus infectivity. J Leukoc Biol 62(1):126\u2013132","journal-title":"J Leukoc Biol"},{"key":"4825_CR170","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1084\/jem.178.2.743","volume":"178","author":"LJ Montaner","year":"1993","unstructured":"Montaner LJ, Doyle AG, Collin M et al (1993) Interleukin 13 inhibits human immunodeficiency virus type 1 production in primary blood-derived human macrophages in vitro. J Exp Med 178:743\u2013747","journal-title":"J Exp Med"},{"issue":"6","key":"4825_CR171","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jmb.2013.11.024","volume":"426","author":"SN Lester","year":"2014","unstructured":"Lester SN, Li K (2014) Toll-like receptors in antiviral innate immunity. J Mol Biol 426(6):1246\u20131264","journal-title":"J Mol Biol"},{"issue":"1","key":"4825_CR172","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/08830185.2010.529976","volume":"30","author":"H Kumar","year":"2011","unstructured":"Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30(1):16\u201334","journal-title":"Int Rev Immunol"},{"key":"4825_CR173","doi-asserted-by":"crossref","unstructured":"Hennessy EJ, Parker AE, O'neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010; 9[4]:293\u2013307","DOI":"10.1038\/nrd3203"},{"key":"4825_CR174","first-page":"353","volume":"76","author":"A Rozy","year":"2008","unstructured":"Rozy A, Chorostowska-Wynimko J (2008) Bacterial immunostimulants \u2014 mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol 76:353\u2013359","journal-title":"Pneumonol Alergol Pol"},{"key":"4825_CR175","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF02850109","volume":"18","author":"SB Ruah","year":"2001","unstructured":"Ruah SB, Ruah C, van Aubel A, Abel S, Elsasser U (2001) Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections. Adv Ther 18:151\u2013162","journal-title":"Adv Ther"},{"key":"4825_CR176","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09737","volume":"470","author":"SP Kasturi","year":"2011","unstructured":"Kasturi SP, Skountzou I, Albrecht RA et al (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543\u2013547","journal-title":"Nature"},{"issue":"3","key":"4825_CR177","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2249.2010.04196.x","volume":"161","author":"M Carty","year":"2010","unstructured":"Carty M, Bowie AG (2010) Recent insights into the role of Toll-like receptors in viral infection. Clin Exp Immunol 161(3):397\u2013406","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"4825_CR178","first-page":"133","volume":"62","author":"MJ Cannon","year":"1987","unstructured":"Cannon MJ, Stott EJ, Taylor G et al (1987) Clearance of persistent respiratory syncytial virus infections immune deficient mice following transfer primed. T cells Immunology 62(1):133\u2013138","journal-title":"T cells Immunology"},{"issue":"2","key":"4825_CR179","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","volume":"18","author":"MN Wykes","year":"2018","unstructured":"Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18(2):91\u2013104. https:\/\/doi.org\/10.1038\/nri.2017.112","journal-title":"Nat Rev Immunol"},{"key":"4825_CR180","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.peptides.2014.01.022","volume":"54","author":"BP Singh","year":"2014","unstructured":"Singh BP, Vij S, Hati S (2014) Functional significance of bioactive peptides derived from soybean. Peptides 54:171\u2013179","journal-title":"Peptides"},{"key":"4825_CR181","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389\u2013395","journal-title":"Nature"},{"key":"4825_CR182","first-page":"3919","volume":"11","author":"J Lei","year":"2019","unstructured":"Lei J, Sun L, Huang S et al (2019) The antimicrobial peptides and their potential clinical applications. Am J Transl Res 11:3919","journal-title":"Am J Transl Res"},{"key":"4825_CR183","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.2174\/138161211798999348","volume":"17","author":"E Arnett","year":"2011","unstructured":"Arnett E, Seveau S (2011) The multifaceted activities of mammalian defensins. Curr Pharm Des 17:4254\u20134426","journal-title":"Curr Pharm Des"},{"key":"4825_CR184","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nchembio.1393","volume":"9","author":"AL Hilchie","year":"2013","unstructured":"Hilchie AL et al (2013) Immune modulation by multifaceted cationic host defense [antimicrobial] peptides. Nat Chem Biol 9:761\u2013768","journal-title":"Nat Chem Biol"},{"key":"4825_CR185","first-page":"5707","volume":"276","author":"J Harder","year":"2001","unstructured":"Harder J, Bartels J, Christophers E et al (2001) Isolation and characterization of human \u03b2-defensin-3, a novel human inducible peptide antibiotic. J BiolChem 276:5707\u20135713","journal-title":"J BiolChem"},{"key":"4825_CR186","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1172\/JCI112120","volume":"76","author":"T Ganz","year":"1985","unstructured":"Ganz T, Selsted ME, Szklarek D et al (1985) Defensins. Natural peptide antibiotics of human neutrophils. J Clin Investig 76:1427\u20131435","journal-title":"J Clin Investig"},{"key":"4825_CR187","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1128\/jvi.60.3.1068-1074.1986","volume":"60","author":"KA Daher","year":"1986","unstructured":"Daher KA, Selsted ME, Lehrer RI (1986) Direct inactivation of viruses by human granulocyte defensins. J Virol 60:1068\u20131074","journal-title":"J Virol"},{"key":"4825_CR188","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/eji.200737292","volume":"37","author":"A Soruri","year":"2007","unstructured":"Soruri A, Grigat J, Forssmann U et al (2007) \u03b2-Defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells. Eur J Immunol 37:2474\u20132486","journal-title":"Eur J Immunol"},{"key":"4825_CR189","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.286.5439.525","volume":"286","author":"D Yang","year":"1999","unstructured":"Yang D, Chertov O, Bykovskaia SN et al (1999) \u03b2-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525\u2013528","journal-title":"Science"},{"key":"4825_CR190","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1074\/jbc.271.6.2935","volume":"271","author":"O Chertov","year":"1996","unstructured":"Chertov O, Michiel DF, Xu L et al (1996) Identification of defensin-1, defensin-2, and CAP37\/azurocidin as T-cell chemoattractant proteins released from interleukin-8- stimulated neutrophils. J Biol Chem 271:2935\u20132940","journal-title":"J Biol Chem"},{"key":"4825_CR191","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-virology-101416-041734","volume":"4","author":"MK Holly","year":"2017","unstructured":"Holly MK, Diaz K, Smith JG (2017) Defensins in viral infection and pathogenesis. Annu Rev Virol 4:369\u2013391","journal-title":"Annu Rev Virol"},{"key":"4825_CR192","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3389\/fmicb.2020.01155","volume":"11","author":"C Chessa","year":"2020","unstructured":"Chessa C, Bodet C, Jousselin C et al (2020) Antiviral and immunomodulatory properties of antimicrobial peptides produced by human keratinocytes. Fron microbiol 11:1155","journal-title":"Fron microbiol"},{"issue":"12","key":"4825_CR193","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood.V97.12.3951","volume":"97","author":"OE S\u00f8rensen","year":"2001","unstructured":"S\u00f8rensen OE, Follin P, Johnsen AH et al (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97(12):3951\u20133959","journal-title":"Blood"},{"key":"4825_CR194","doi-asserted-by":"crossref","unstructured":"Rivas-Santiago B, Casta\u00f1eda-Delgado JE, Rivas Santiago CE, et al. Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models. PloS one. 2013;8[3]:e59119.","DOI":"10.1371\/journal.pone.0059119"},{"key":"4825_CR195","doi-asserted-by":"crossref","unstructured":"SteinstraesserL, Hirsch T, Schulte M, et al. Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS One. 2012;7[8]:e39373","DOI":"10.1371\/journal.pone.0039373"},{"issue":"3","key":"4825_CR196","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.24087","volume":"75","author":"H Bolouri","year":"2014","unstructured":"Bolouri H, S\u00e4vman K, Wang W et al (2014) Innate defense regulator peptide 1018 protects against perinatal brain injury. Ann Neurol 75(3):395\u2013410","journal-title":"Ann Neurol"},{"issue":"2","key":"4825_CR197","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.antiviral.2013.08.019","volume":"100","author":"A Shestakov","year":"2013","unstructured":"Shestakov A, Jenssen H, Hancock RE et al (2013) Synthetic analogues of bovine bactenecindodecapeptide reduces herpes simplex virus type 2 infectivity in mice. Antiviral Res 100(2):455\u2013459","journal-title":"Antiviral Res"},{"key":"4825_CR198","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrmicro1273","volume":"3","author":"PD Cotter","year":"2005","unstructured":"Cotter PD, Hill C, Ross RP (2005) Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 3:777\u2013778","journal-title":"Nat Rev Microbiol"},{"key":"4825_CR199","unstructured":"A specific peptide with immunomodulatory activity from Pseudostellaria heterophylla and the action mechanism"},{"key":"4825_CR200","doi-asserted-by":"publisher","first-page":"151936","DOI":"10.1016\/j.imbio.2020.151936","volume":"225","author":"J Cai","year":"2020","unstructured":"Cai J, Li X, Du H, Jiang C et al (2020) Immunomodulatory significance of natural peptides in mammalians: Promising agents for medical application. Immunobiology 225:151936","journal-title":"Immunobiology"},{"key":"4825_CR201","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/v11080704","volume":"11","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Siman-Tov G, Hall G et al (2019) Human Antimicrobial Peptides as Therapeutics for Viral Infections. Viruses 11:704. https:\/\/doi.org\/10.3390\/v11080704","journal-title":"Viruses"},{"issue":"4","key":"4825_CR202","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.it.2019.02.002","volume":"40","author":"RD Paucek","year":"2019","unstructured":"Paucek RD, Baltimore D, Li G (2019) The cellular immunotherapy revolution: arming the immune system for precision therapy. Trends Immunol 40(4):292\u2013309","journal-title":"Trends Immunol"},{"issue":"2","key":"4825_CR203","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/0042-6822(92)90554-3","volume":"188","author":"K Saha","year":"1992","unstructured":"Saha K, Wong PK (1992) Protective role of cytotoxic lymphocytes against murine leukaemia virus-induced neurologic disease and immunodeficiency is enhanced by the presence of helper T cells. Virol 188(2):921\u2013925","journal-title":"Virol"},{"key":"4825_CR204","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","volume":"65","author":"GA Sautto","year":"2016","unstructured":"Sautto GA, Wisskirchen K, Clementi N et al (2016) Chimeric antigen receptor [CAR]-engineered T cells redirected against hepatitis C virus [HCV] E2 glycoprotein. Gut 65:512\u2013523","journal-title":"Gut"},{"issue":"1","key":"4825_CR205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-018-1394-x","volume":"16","author":"J Proff","year":"2018","unstructured":"Proff J, Brey CU, Ensser A et al (2018) Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2\u2013CH3 IgG spacer domains. J Transl Med 16(1):1\u20132","journal-title":"J Transl Med"},{"key":"4825_CR206","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.trsl.2017.07.002","volume":"187","author":"MA Carrillo","year":"2017","unstructured":"Carrillo MA, Zhen A, Zack JA et al (2017) New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV. Transl Res 187:83\u201392","journal-title":"Transl Res"},{"issue":"7-8","key":"4825_CR207","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1089\/hum.2019.149","volume":"31","author":"H Olbrich","year":"2020","unstructured":"Olbrich H, Theobald SJ, Slabik C et al (2020) Adult and cord blood-derived high-affinity gB-CAR-T cells effectively react against human Cytomegalovirus infections. Hum Gene Ther 31(7\u20138):423\u2013439","journal-title":"Hum Gene Ther"},{"issue":"20","key":"4825_CR208","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1365-2567.1996.tb00008.x","volume":"88","author":"L Lamontagne","year":"1996","unstructured":"Lamontagne L, Jolicoeur P, Decarie D et al (1996) Effect of adoptive transfer of CD4, CD8 and B cells on recovery from MHV3-induced immune deficiencies. Immunology 88(20):220\u2013229","journal-title":"Immunology"},{"key":"4825_CR209","doi-asserted-by":"crossref","unstructured":"Parida SK, Poiret T, Zhenjiang L, et al... T-cell therapy: options for infectious diseases. Arch Clin Infect Dis. 2015;61[suppl_3]:S217\u201324","DOI":"10.1093\/cid\/civ615"},{"issue":"4","key":"4825_CR210","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2217\/imt.09.26","volume":"1","author":"NR Hegde","year":"2009","unstructured":"Hegde NR, Rao PP, Bayry J et al (2009) Immunotherapy of viral infections. Immunotherapy 1(4):691\u2013711","journal-title":"Immunotherapy"},{"issue":"4","key":"4825_CR211","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/icb.2008.15","volume":"86","author":"F Masson","year":"2008","unstructured":"Masson F, Mount AM, Wilson NS et al (2008) Dendritic cells: driving the differentiation programme of T cells in viral infections. Immunol Cell Biol 86(4):333\u2013342","journal-title":"Immunol Cell Biol"},{"key":"4825_CR212","doi-asserted-by":"crossref","unstructured":"Lyse Darwish, Samira Mubareka & W Conrad Liles Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther. 2011:7, 807\u2013822","DOI":"10.1586\/eri.11.56"},{"key":"4825_CR213","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00858-2020","author":"M Khoury","year":"2020","unstructured":"Khoury M, Cuenca J, Cruz FF et al (2020) Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00858-2020","journal-title":"Eur Respir J"},{"issue":"3","key":"4825_CR214","first-page":"105","volume":"68","author":"A Sleem","year":"2020","unstructured":"Sleem A, Saleh F (2020) Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy. Curr Res Transl Med 68(3):105\u2013110","journal-title":"Curr Res Transl Med"},{"key":"4825_CR215","doi-asserted-by":"crossref","unstructured":"Zhen A, Peterson CW, Carrillo MA, et al. Correction: Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV\/AIDS. PLoS Pathog. 2018;14[3]:e1006891.","DOI":"10.1371\/journal.ppat.1006891"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-023-04825-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-023-04825-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-023-04825-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T17:55:54Z","timestamp":1724435754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-023-04825-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":215,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["4825"],"URL":"https:\/\/doi.org\/10.1007\/s11010-023-04825-w","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"9 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the authors agreed to submit the manuscript in the journal. The same has approved by the parent Institute.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent or publication"}}]}}